0 Members and 1 Guest are viewing this topic.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour. https://www.ft.com/content/abea44bf-e6cb-415f-8aee-1487803e154c Scientists at the US regulator found in a report on Wednesday that the J&J jab was 82 per cent effective at preventing severe or critical disease at its trial site in South Africa, where the 501.V2 variant was prevalent. This compares with 86 per cent efficacy in participants in the US and 88 per cent in Brazil, from 28 days after vaccination.The vaccine was less effective at preventing moderate to severe illness in the South African group, at 64 per cent, compared with 72 and 78 per cent at the sites in the US and in Brazil.
those of us who have had the AstraZeneca jab have very little protection against the South African variant, is this right?